Intellia Reports Positive 3-Year Phase 1 Data for Lonvo-z in Hereditary Angioedema
Intellia Therapeutics Reports Positive 3-Year Phase 1 Data for Lonvo-z in Hereditary Angioedema — Highlights Durable Benefit and Safety Intellia Therapeutics, a leading clinical-stage genome-editing biotechnology company, today presented updated…
Sarepta Strengthens ELEVIDYS Safety Measures for Non-Ambulatory Duchenne Patients
Sarepta Takes Action to Strengthen ELEVIDYS Safety Measures in Non-Ambulatory Duchenne Patients Sarepta Therapeutic a leading innovator in precision genetic medicine for rare disorders, today provided a significant safety update…
QIAGEN and Incyte Partner on Companion Dx for Mutant CALR MPNs
QIAGEN and Incyte Forge Global Collaboration to Develop Companion Diagnostic Panel for Patients With Mutant CALR-Positive Myeloproliferative Neoplasms QIAGEN N.V. and Incyte today announced a significant new collaboration aimed at…
Genmab: Epcoritamab Combo Shows High Response in Transplant-Eligible R/R DLBCL
Genmab Presents Positive Epcoritamab Combination Data in Relapsed or Refractory DLBCL Eligible for Autologous Stem Cell Transplantation Genmab A/S today shared new and highly promising data from its Phase 1b/2…
EAACI: Dupixent Supersedes Xolair in CRS w/ Nasal Polyps and Asthma Phase 4 Head-to-Head Study
Sanofi and Regeneron’s Dupixent Shows Superiority over Xolair in First-Ever Head-to-Head Phase 4 Study in Patients with Severe Chronic Rhinosinusitis with Nasal Polyps and Co-existing Asthma Sanofi and Regeneron Pharmaceuticals,…
Roche shares Elevidys safety update in non-ambulatory Duchenne muscular dystrophy patients
Roche Suspends Elevidys Dosing in Non-Ambulatory DMD Patients Amid Safety Concerns Roche today announced a significant update to its dosing guidelines for Elevidys™ (delandistrogene moxeparvovec), following a careful reassessment of…
TALVEY + TECVAYLI Provide Durable Responses in Extramedullary Multiple Myeloma
Johnson & Johnson’s RedirecTT-1 Study Shows Durable Responses in Heavily Pretreated Multiple Myeloma Patients with Extramedullary Disease Johnson & Johnson today presented new and promising data from its Phase 2…
Elanco’s Zenrelia Wins Positive CVMP Opinion
Elanco’s Zenrelia (ilunocitinib) Wins Positive CVMP Opinion, Paving the Way for EU Approval and Market Release Elanco Animal Health Incorporated (NYSE: ELAN) today announces a significant milestone in its ongoing…
mRNA Tech Transfer Phase 2.0 Discussed at G20 Summit
mRNA Technology Transfer Programme Moves Into Phase 2.0, Boosting Sustainable Local Vaccine Manufacturing and Global Health Security In parallel with the G20 Health Working Group meeting, global health leaders and…
Astellas, Mitsubishi Research Institute Team Up to Support Japanese Pharma Startups
Mitsubishi Research Institute and Astellas Forge Collaborative Initiative to Support Japanese Drug Discovery Startups and Boost Global Innovation Mitsubishi Research Institute, Inc. (MRI) and Astellas Pharma Inc. (Astellas) today announced…
Amgen & Barry Sanders Spotlight Bad Cholesterol Risks in Documentary
Amgen and Barry Sanders Raise Awareness About “Bad Cholesterol” in Documentary Highlighting Cardiovascular Disease Crisis in America Amgen today announced the launch of The Making of a Heart Attack, a…
FDA Approves KEYTRUDA for Neoadjuvant and Adjuvant Treatment of PD-L1+ Resectable Head & Neck Cancer
FDA Approves KEYTRUDA® (Pembrolizumab) for Perioperative Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma Merck known as MSD outside the United States and Canada, recently announced that…